Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Growth hormone (GH) deficiency (GHD) in children is defined as impaired production of GH
by the pituitary gland that results in growth failure. This disease might be congenital or …

Daily recombinant human GH (rhGH) is currently approved for use in children and adults
with GH deficiency (GHD) in many countries with relatively few side-effects. Nevertheless …

Context Somapacitan, a once-weekly reversible albumin-binding GH derivative, is evaluated
in children with GH deficiency (GHD). Objective To demonstrate efficacy and safety of …

We evaluated the efficacy, safety, adherence, quality of life (QoL) and cost-effectiveness of
long-acting growth hormone (LAGH) vs daily growth hormone (GH) preparations in the …

Context Growth hormone deficiency (GHD) in children is currently treated with daily
injections of GH, which can be burdensome for patients and their parents/guardians …

The excellent properties of polyesters combined with their ease of synthesis and
modification enabled their wide use in the pharmaceutical industry. This has been translated …

Context Current GH therapy requires daily injections, which can be burdensome.
Somapacitan is a long-acting GH derivative in development for treatment of GH deficiency …

Individuals surviving cancer and brain tumors may experience growth hormone (GH)
deficiency as a result of tumor growth, surgical resection and/or radiotherapy involving the …

In standard 52-week phase III clinical trials, once weekly lonapegsomatropin, somatrogon
and somapacitan have been found to yield non-inferior height velocities and similar safety …